KdT Ventures today announced the successful close of its oversubscribed fourth fund (Fund IV), raising over $100 million to support early-stage, science-driven companies. Fund IV is the firm’s largest fund to date, and follows KdT’s previous $80 million Fund III which was announced in 2022. The firm’s total assets under management now exceed $250 million.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,